Equities

Hansoh Pharmaceutical Group Company Ltd

Hansoh Pharmaceutical Group Company Ltd

Actions
  • Price (EUR)2.06
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+21.89%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Hansoh Pharmaceutical Group Company Ltd grew revenues 7.69% from 9.38bn to 10.10bn while net income improved 26.85% from 2.58bn to 3.28bn.
Gross margin91.01%
Net profit margin38.97%
Operating margin45.06%
Return on assets14.82%
Return on equity18.10%
Return on investment17.87%
More ▼

Cash flow in CNYView more

In 2023, Hansoh Pharmaceutical Group Company Ltd increased its cash reserves by 124.31%, or 3.31bn. The company earned 3.12bn from its operations for a Cash Flow Margin of 30.84%. In addition the company generated 1.07bn cash from investing, though they paid out 753.70m more in financing than they received.
Cash flow per share0.9239
Price/Cash flow per share18.52
Book value per share5.12
Tangible book value per share5.08
More ▼

Balance sheet in CNYView more

Hansoh Pharmaceutical Group Company Ltd has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 22.43bn.
Current ratio7.98
Quick ratio7.81
Total debt/total equity0.0043
Total debt/total capital0.0043
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)24.45%
EPS growth(5 years)8.11
EPS (TTM) vs
TTM 1 year ago
81.07
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.